ARCHIVES

Phase 0 Trials Signal FDA’s New Reliance On Biomarkers For Drug Development.

This article is from The Cancer Letter archive.

Vol. 32 No. 01 | January 13, 2006

Download PDF Visit The Full Archive

Related Articles

NCAB Approves Characteristics for Recognition As Comprehensive; Outlook Dim for New Division

May 19, 1989

Sponsors Withdraw Indications for Iressa, Celebrex

February 11, 2011

Fondaparinux Prevents DVT In Acutely III Medical Patients

January 30, 2004

Cooperative Groups Other Investigators To Get Interferon When Available; DCT Recompetitions Okayed

April 4, 1980

North General, MSK, Form Cancer Prevention Center.

June 30, 2000

NCI, CDC To Collaborate On Surveillance System.

March 24, 2000